Exemestane and aromatase inhibitors in the management of advanced breast cancer

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 2, 2004, Pages 307-316

  Dixon, J Michael ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Adjuvant; Anastrozole; Antiaromatase; Aromatase inactivator; Aromatase inhibitor; Cross resistance; Exemestane; Letrozole; Neoadjuvant; Oestrogen; Tamoxifen

Indexed keywords

ALKALINE PHOSPHATASE; AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROSTENEDIONE; AROMATASE; AROMATASE INHIBITOR; CORTICOSTEROID; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; MEGESTROL ACETATE; PROGESTERONE; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TYROSINE KINASE RECEPTOR; VOROZOLE;

ADVANCED CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CLINICAL TRIAL; CROSS RESISTANCE; DOSE RESPONSE; DRUG BINDING; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; ENZYME INHIBITION; HORMONAL THERAPY; HOT FLUSH; HUMAN; LETHARGY; MUSCULOSKELETAL DISEASE; ORTHOSTATIC HYPOTENSION; POSTMENOPAUSE; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SWEATING; VAGINA BLEEDING; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANDROSTADIENES; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; GREAT BRITAIN; HUMANS;

EID: 1242274385     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.2.307     Document Type: Review

References (47)

1. IBRAHIM NK, BUZDAR AU: Aromatase inhibitors: current status. Am. J. Clin. Oncol. (CCT) (1995) 18:407-417.
2. KAUFMANN M, VON MINCKWITZ G: New hormones. In: Textbook of Breast Cancer: A Clinical Guide to Therapy. Bonadonna G, Hortobagyi GN, Gianni AM (Eds), Dunitz, London, UK (1997):281-304.
3. EVANS CT, LEDESMA DB, SCHULZ TZ, SIMPSON ER, MENDELSON CR: Isolation and characterization of a complementary DNA specific for human aromatase-system cytochrome P450 mRNA. Proc. Natl. Acad. Sci. USA (1986) 83:6387-6391.
4. HARVEY HA: Aromatase inhibitors in clinical practice: current status and a look to the future. Semin. Oncol. (1996) 23(Suppl. 9):33-38.
5. REED MJ: The role of aromatase in breast tumours. Breast. Cancer. Res. Treat. (1994) 30:7-17.
6. SIMPSON ER, CLYNE C, RUBIN G et al.: Aromatase - a brief overview. Ann. Rev. Physiol. (2002) 64:93-127.
7. LØNNING PE: Aromatase inhibitors and inactivators in breast cancer. Br. Med. J. (2001) 323:880-881.
8. SMITH IE, DOWSETT M: Aromatase inhibitors in breast cancer. N. Engl. J. Med. (2003) 348(24):2431-2442.
9. ALLRED DC, BAUM M, BUZDAR AU et al.: A roundtable discussion of aromatase inhibitors as therapy for breast cancer. Breast J. (2003) 9(3):213-222.
10. GOSS PE: Emerging role of aromatase inhibitors in the adjuvant setting. Am. J. Clin. Oncol. (2003) 26(4):S27-S33.
11. GOSS P: Anti-aromatase agents in the treatment and prevention of breast cancer. Cancer Control. (2002) 9(2 Suppl.):2-8.
12. GOSS PE, STRASSER K: Aromatase inhibitors in the treatment and prevention of breast cancer. J. Clin. Oncol. (2001) 19:881-894.
13. MILLER WR, DIXON JM: Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin. Breast. Cancer. (2000) 1(Suppl. 1):S9-S14.
14. DOWSETT M, JONES A, JOHNSTON SRD, JACOBS S, TRUNET P, SMITH IE: In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin. Canc. Res. (1995) 1:1511-1515.
15. GEISLER J, KING N, DOWSETT M et al.: Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br. J. Cancer (1996) 74:1286-1291.
16. GEISLER J, KING N, ANKER G et al.: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin. Cancer. Res. (1998) 4:2089-2093.
17. GEISLER J, HAYNES B, ANKER G et al.: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol. (2002) 20(3):751-757.
18. CHEN S, ZHOU D, OKUBO T et al.: Breast tumor aromatase: functional role and transcriptional regulation. Endocr. Relat. Cancer. (1999) 6:149-156.
19. HARADA N, HONDA SI, HATANO O: Aromatase inhibitors and enzyme stability. Endocr. Relat. Cancer. (1999) 6:211-218.
20. ELLIS MJ, COOP A, SINGH B et al.: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2 positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J. Clin. Oncol. (2001) 19:3808-3816.
21. MURRAY P, PITT P: Aromatase inhibition with 4-OHAdrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast. Cancer. Res. Treat. (1995) 35:249-253.
22. GEISLER J, JOHANNESSEN DC, ANKDER G et al.: Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects. Eur. J. Cancer. (1996) 32A:789-792.
23. LØNNING PE, BAJETTA E, MURRAY R et al.: Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A Phase II trial. J. Clin. Oncol. (2000) 8(11):2234-2244.
24. BERTELLI G, GARRONE O, MERLANO M: Sequential use of aromatase inactivators and inhibitors in advanced breast cancer: Annual meeting of the American Society of Clinical Oncology (2002) 238 (Abstract).
25. BUZDAR A, JONAT W, HOWELL A et al.: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature Phase III trials. Cancer (1998) 83:1142-1152.
26. DOMBERNOWSKY P, SMITH I, FALKSON G et al.: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol. (1998) 16:453-461.
27. KAUFMANN M, BAJETTA E, DIRIX LY et al.: Exemestane is superior to megestrol acetate after ramoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. J. Clin. Oncol. (2000) 18(7):1399-1411.
28. MOURIDSEN H, GERSHANOVICH M, SUN Y et al.: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. (2001) 19:2596-2606 [Erratum: J. Clin. Oncol. (2001) 19:3302].
29. NABHOLTZ JM, BUZDAR A, POLLAK M et al.: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast carcinoma in postmenopausal women: results of a North American multicenter randomized trial. J. Clin. Oncol. (2000) 18:3758-3767.
30. BONNETERRE J, THÜRLIMANN B, ROBERTSON JFR et al.: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J. Clin. Oncol. (2000) 18:3748-3757.
31. PARIDAENS R, DIRIX L, BEEX L et al.: Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized Phase II EORTC trial with a tamoxifen control. Clin. Breast. Cancer. (2002) 1(1):S19-S21.
32. DIRIX L, PICCART MJ, LOHRISH C et al.: Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) Phase II trial with Pharmacia & Upjohn. Proc. Am. Soc. Clin. Oncol. (2001) 20:29a (Abstract).
33. THE ATAC (ARIMIDEX, TAMOXIFEN ALONE OR IN COMBINATION) TRIALISTS' GROUP: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet (2002) 359:2131-2139.
34. POWLES TJ, HICKISH T, KANIS JA, TIDY A, ASHLEY S: Effects of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J. Clin. Oncol. (1996) 14:78-84.
35. LOVE RR, BARDEN HS, MAZESS RB, EPSTEIN S, CHAPPELL RJ: Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch. Intern. Med. (1994) 154:2585-2588.
36. HARPER-WYNNE C, ROSS G, SACKS N et al.: Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer. Epidemiol. Biomarkers. Prev. (2002) 11:614-621.
37. LØNNING P: Clinical pharmacokinetics of aromatase inhibitors and inactivators. Clin. Pharmacokinet. (2003) 42(7):619-631.
38. MORTIMER JE, URBAN JH: Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents. Oncology (Huntingt) (2003) 17(5):652-659.
39. GOSS P, GRYNPAS M, QI S, HU H: The effects of exemestane on bone and lipids in the ovariectomized rat. Presented at the 24th Annual San Antonio Breast Cancer Symposium. San Antonio, USA (2001).
40. ZILEMBO N, BAJETTA E, MARTINETTI A et al.: Markers of bone turnover in metastatic breast cancer (MBC) patients having progressed on tamoxifen: short term effect of further treatment with either exemestane (EXE) or megestrol acetate (MA) (abstract 707). Eur. J. Cancer. (2001) 37(Suppl. 6):S193.
41. BEAR H: Indications for neoadjuvant therapy for breast cancer. Semin. Oncol. (1998) 25(Suppl. 3):3-12.
42. DIXON JM, ANDERSON TJ, MILLER WR: Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur. J. Cancer. (2002) 38:2214-2221.
43. DIXON JM: Neoadjuvant therapy: surgical perspectives. In: Endocrine Therapy in Breast Cancer. Miller WR, Ingle JR (Eds), Marcel Dekker, Inc., New York (2002):197-212.
44. SMITH I, DOWSETT M, on behalf of the IMPACT TRIALISTS: Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Presented at the 26th San Antonio Breast Cancer Symosium, San Antonio, Texas, USA, December 3-6 (2003).
45. MILLER WR, DIXON JM: Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control. (2002) 9(Suppl.):9-15.
46. GIL M: Neoadjuvant exemestane in breast Cancer. Poster presented at the 25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, December 11-14 (2002).
47. SEMINGLAZOV VF et al.: Exemestane and tamoxifen as neoadjuvant breast cancer therapy: a pilot trial. Poster 9, presented at the Future of Breast Cancer Congress, August, Canada (2003).